The release of therapeutic drugs from the surface of implantable devices is instrumental for the reduction of medical costs and toxicity associated with systemic administration. In this study we demonstrate the triblock copolymer-mediated deposition and release of multiple therapeutics from a single thin fi lm at the air-water interface via Langmuir-Blodgett deposition. The dual drug elution of dexamethasone (Dex) and doxorubicin hydrochloride (Dox) from the thin fi lm is measured by response in the RAW 264.7 murine macrophage cell line. The integrated hydrophilic and hydrophobic components of the polymer structure allows for the creation of hybrids of the copolymer and the hydrophobic Dex and the hydrophilic Dox. Confi rmation of drug release and functionality was demonstrated via suppression of the interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFα) infl ammatory cytokines (Dex), as well as TUNEL staining and DNA fragmentation analysis (Dox). The inherent biocompatibility of the copolymeric material is further demonstrated by the lack of infl ammation and apoptosis induction in cells grown on the copolymer fi lms. Thus a layer-by-layer anchored deposition of an anti-infl ammatory and chemotherapeutic functionalized copolymer fi lm is able to localize drug dosage to the surface of a medical device, all with an innate material thickness of 4 nm per layer.
Introduction
The application of therapeutic drugs to a patient can lead to numerous complications. Most anti-cancer chemotherapies lack cellular specifi city, thus systemic administration inevitably causes adverse reactions in patients (Sridhar et al 1992; Gerweck et al 1999; Wang et al 1999; Kimura et al 2000; Kang et al 2002; Olson et al 2003) through the indiscriminate induction of cell death (Arola et al 2000; Kotamraju et al 2000; Wang et al 2004; Eom et al 2005; Hou et al 2005) of cancerous and noncancerous tissues. Likewise, systemically administered anti-infl ammatory steroids have been shown to interfere with other treatments. For example, the administration of glucocorticoid antiinfl ammatories used to treat infl ammatory conditions in cells can interfere with the progression of apoptosis by various anti-cancer chemotherapies, including paclitaxel and doxorubicin (Moran et al 2000; Mikosz et al 2001; Wu et al 2004) . The intersection of nanomaterials and medicine has generated platform technologies incorporating various methodologies for fi lm-based drug release and particle based systemic drug administration and circulation. Nanoparticles engineered to contain targeting elements can produce a desired response in cells that present upregulated markers that are indicative of the targeted condition (eg, cancerous, diseased) . Nanoparticle based therapeutic delivery systems include diamond-based materials (Chen et al 2007; Huang et al 2007 Huang et al , 2008 , metallic nanoparticles (Oishi et al 2006; Rosi et al 2006) , and functionalized micelles and liposomes (Yoo et al 2001 (Yoo et al , 2004 Greish et al 2004) . Film-based local-release modalities have further been employed for drug therapy which generate a concentrated response at the site of implantation and do not rely on systemic drug transport. These thin fi lm technologies include coatings to protect implants against breakdown/degradation through infl ammatory immune responses (Ariga et al 2006; Pierstorff and Ho 2007; Chow et al 2008) . Due to the localized and directed nature of this fi lm based therapy, it is a platform through which a wide variety of clinical conditions can be targeted.
Previously, we have demonstrated the use of polymethyloxazoline-polydimethylsiloxane-polymethyloxazoline (PMOXA-PDMS-PMOXA) block copolymer membranes for harnessing and releasing active anti-infl ammatory and anticancer therapeutics (Chow et al 2008; Pierstorff et al 2008) . This copolymer contains both hydrophilic and hydrophilic blocks which allows for the formation of copolymer-drug hybrids that incorporate therapeutics of virtually any type regardless of its hydrophilic or hydrophobic characteristics (Nardin et al 2000 (Nardin et al , 2001 Ho et al 2003 Ho et al , 2004 . The polymer has also been shown to be biocompatible and is only 4 nm thick, making it noninvasive and an ideal candidate for a fi lm based drug eluting platform for medical devices. This study has combined the benefi ts of thin fi lm polymers with localized drug delivery to fabricate a block copolymer nanofi lm capable of eluting multiple therapeutics from a single device (Figure 1 ). These include dexamethasone (Dex), a steroid based anti-infl ammatory and doxorubicin hydrochloride (Dox), an anti-cancer therapeutic that induces cell death via apoptosis. Surface pressure isotherms were used to confi rm fi lm formation and drug mixing, and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), TUNEL-based cell staining, and DNA fragmentation studies were performed to ascertain drug release and function. Thus a multifunctional thin fi lm coating to address multiple conditions simultaneously was created.
Materials and methods
Raw 264.7 murine macrophage culture Nanomembrane-driven co-elution and integration 1% penicillin/streptomycin at 37 °C with 5% carbon dioxide. Cells were plated onto the fabricated substrate slides (glass, polymer only, or polymer-drug) and grown for the indicated time points. For infl ammation studies, 5 ng/mL lipopolysaccharide (LPS) (Sigma, St. Louis, MO) was added for the last 4 hours of incubation followed by cell harvesting. For apoptosis studies, an additional 10% of FBS was added to the cell culture every 24 hours to prevent serum starvation.
Anti-infl ammatory and chemotherapeutic Langmuir-Blodgett fi lm fabrication
Langmuir-Blodgett (LB) fi lms were fabricated using a KSV 2000 Standard Langmuir Trough with a Tefl on ® base, Delrin barriers, platinum Wilhemy pressure sensor, and a subphase of water. The entire trough was covered with a plastic case with an integrated door to enable manual manipulation/cleaning of the trough. The base was cleaned with multiple washings with methanol and nanopure water using a lint free wipe to ensure trough cleanliness and the trough was then fi lled with nanopure water. The Wilhemy platinum pressure sensing plate (stored in MeOH) was thoroughly rinsed using nanopure water and heat-sterilized just before use. The pressure sensor was zeroed immediately prior to fi lm deposition or isotherm reading.
Dexamethasone (Sigma) was dissolved in 100% ethanol to a concentration of 5 mg/ml and Doxorubicin (US Pharmacopeia, Rockville, MD) was dissolved in nanopure water to a concentration of 2.5 mg/ml. The drugs (60 μl dexamethasone, 400 μl doxorubicin) were then added to an interfacial pre-formed 20 mN/m copolymer fi lm (Polymer Source, Montreal, QU, Canada) and changes in surface pressure were monitored to confi rm drug presence at the air-water interface. After 30 minutes of allowing the fi lm to reach equilibrium, compressions were performed at a rate of 1mm/min to a maximum pressure of 25 mN/m for LB deposition onto glass slides (25 mm × 75 mm) at a rate of 1mm/min. Films were compressed to Ͼ50 mN/m until collapse for Langmuir fi lm characterization of fi lm properties. Three layers of drug-functionalized polymer were deposited and used for the studies.
Polymer-dexamethasone-driven suppression of infl ammatory gene expression RAW 264.7 cells were plated onto the fabricated substrate slides (glass, polymer only, or polymer-drug) and grown for 24 hours at 37 °C with 5% carbon dioxide. Cells were stimulated with LPS for 4 hours, followed by cell harvesting. RT-PCR was performed for gene expression analysis to refl ect fi lm functionality as described previously . Briefl y, TRIzol reagent (Invitrogen, Carlsbad, CA) was added to each sample to collect the RNA. Subsequent RNA isolation was performed according to the manufacturer's protocol, RNA was converted to cDNA using the I-script enzyme (Bio-Rad, Hercules, CA). Real time PCR analysis (Bio-Rad) was performed monitoring the expression of the genes interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFα) at each time point. Control primers (β-actin) were used to normalize for cDNA concentration variation. Primer sequences utilized are as follows: TNFα: 5'-GGTGCCTATGTCT-CAGCCTCTT-3' and 5'-CGATCACCCCGAAGTTCAGT1, IL-6: 5'-CACAGAGGATAC-CACTCCCAACA-3' and 5' TCCACGATTTCCCAGAGAACA-3', β-actin: 5'-TGGAATCCTGTGGCATCCATGAAAC-3' and 5'-TAAAACGCAGCTCAGTAACAGTCCG-3'.
DNA fragmentation assay for chemotherapeutic nanofi lms RAW 264.7 cells were plated onto the fabricated substrate slides (glass, polymer only, or polymer-drug) and grown for 67 hours at 37 °C with 5% carbon dioxide. Cultures were supplemented with an additional 10% FBS every 24 hours to prevent serum starvation. Cellular DNA was purifi ed as described previously . Briefl y, cells were lysed in 500 μL lysis buffer (10 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% Triton X-100) follwed by 30-minute incubations with RNase A and proteinase K, separately. After phenol chloroform extraction, nuclear DNA was precipitated in isopropyl alcohol, washed in 70% ethanol, and resuspended in DEPC water. Samples were electrophoresed on 0.8% agarose gel, and stained with ethidium bromide.
Confocal microscopy for TUNEL assay RAW 264.7 cells were plated onto the fabricated substrate slides (glass, polymer only, or polymer-drug) and grown for 67 hours at 37 °C with 5% carbon dioxide. Cultures were supplemented with an additional 10% FBS every 24 hours to prevent serum starvation. The TUNEL based ApopTag ® Plus Fluorescein In Situ Apoptosis Detection Kit (Chemicon International, Temecula, CA) was used for cell staining to detect apoptosis positive cells following the manufacturer's protocol. Propidium iodide was used for counterstain. Cells were imaged using a Leica inverted microscope Confocal Laser Scanning System and a 40x oil immersion objective. Images were obtained using the Leica Confocal imaging software. Fluorescein was excited at a wavelength of 494 nm and emission was monitored at 518 nm. Propidium iodide was excited at a wavelength of 536 nm and emission was monitored at 617 nm.
Results

Anti-infl ammatory-chemotherapy copolymeric nanofi lm fabrication
Mixtures of copolymers with the drugs Dex and Dox were characterized via Langmuir isotherms and copolymerDex-Dox thin fi lms were fabricated via Langmuir-Blodgett deposition. Figure 2 shows the compression isotherms for the PMOXA-PDMS-PMOXA triblock copolymer nanofi lm alone or mixed with Dox, Dex, or both Dex and Dox. The variations in the isotherms of the copolymer-drug mixtures demonstrate that the readings were responsive to varied drug amounts and that this mixture was able to generate high surface pressure readings indicative of fi lm formation. These graphs show that drug integration into the copolymer fi lm occurs due to changes between compression phase transitions and maximum collapse pressures. These graphs are similar to the variations in surface pressure that have been seen when drugs have been incorporated into a copolymer thin fi lm at the air-water interface using Langmuir-Blodgett . Copolymer fi lms mixed with either Dex or Dox alone have been previously characterized and demonstrate incorporation of either drug into the copolymer matrix (Chow et al 2008; Pierstorff et al 2008) . Interestingly, when both Dox and Dex are mixed with the copolymer nanofi lm and compressed, the isotherm completely overlaps that of copolymer and Dex alone. Thus, even though the copolymer-Dox mixture alone has a shift in the isotherm (Figure 2 ; Pierstorff et al 2008) , it appears that this is masked or overwhelmed by the presence of Dex in the mixture as well. While the mechanism driving this observation was unclear, Dox activity assays revealed its incorporation into the copolymer nanofi lm.
Polymer-dexamethasone-induced suppression of infl ammatory gene expression
Dex incorporation and release from the deposited polymerDex-Dox thin fi lms was monitored via the infl ammation of cells grown on the polymer-Dex-Dox fi lms with LPS followed by quantitative RT-PCR trials to examine the Dex-mediated suppression of IL-6 and TNFα expression ( Figures 3A and 3B ). IL-6 gene expression was signifi cantly lower in cells grown on polymer-Dex-Dox fi lms, suggesting that the drug was both present in the fi lm and accessible to the cells frown on the slide ( Figure 3A) . As a control for Dex mediated cellular infl ammation suppression, aqueous Dex was added directly to the media of cells infl amed with LPS. The reduction in IL-6 expression was comparable in cells grown on the polymer-Dex-Dox fi lms ( Figure 3A) . Furthermore, the TNFα locus was used as an additional demonstration of infl ammation reduction in cells grown on Gene expression assays with aqueous Dex added were conducted as a control for Dex activity. Results further indicated the incorporation of Dex into the copolymer-Dex-Dox thin fi lm and a potent drug releasing activity as shown through a substantial reduction in infl ammatory gene expression. The broad suppression of infl ammatory gene expression demonstrates an effi cient hybrid nanofi lm system for an active drug delivery interface. Data was acquired and responses were observed from a minimum of three trials.
polymer-Dex-Dox. As with IL-6, there was signifi cant and comparable reduction of TNFα expression in cells grown on the polymer-Dex-Dox fi lms ( Figure 3B ).
Doxorubicin-copolymer driven cellular apoptosis
Confi rmation of copolymer-mediated Dox incorporation and release from polymer-Dex-Dox was also performed using RAW 264.7 macrophage cells. Studies examining Dox-induced DNA fragmentation as well as apoptosis induction and cellular viability via confocal microscopy (TUNEL assays) were used to monitor the onset of apoptosis. DNA fragmentation is an indication of cellular apoptosis (Hassan et al 2005) . Analysis of polymer-Dex-Dox induced apoptosis was performed via the electrophoresis of cellular DNA and looking for the accumulation of the characteristic laddering of fragmented DNA. The polymer-Dex-Dox hybrids generated a very pronounced DNA fragmentation pattern comparable to that of polymer-Dox hybrids previously characterized, thus demonstrating that Dox was both present in the copolymer fi lms and accessible to the cells grown on the fi lms (Figure 4 ). Both the glass-only and the polymer-only control conditions revealed the absence of DNA laddering, thus demonstrating the induction of apoptosis from the polymer-Dex-Dox hybrids as Dox-dependent and providing further supporting evidence for the biocompatibility of the copolymer nanofi lm. Confocal microscopy also revealed the impact of Dox elution from the copolymeric nanofi lm upon cellular morphology and apoptosis progression via a TUNEL based staining assay ( Figure 5 ). The polymer-Dex-Dox and polymer-Dox hybrids produced enlarged cellular morphologies that were indicative of pre-apoptotic cells. Glass-only and polymer-only control slides produced cells with unaltered morphologies. In addition, though the same number of cells were seeded per slide, signifi cantly fewer cells grew and propagated on the polymer-Dex-Dox and polymer-Dox hybrid slides. When staining for double stranded breaks indicative of apoptosis progression, none was seen in cells grown on glass or polymer only slides. However, in both the polymerDox and the polymer-Dex-Dox slides, an accumulation of apoptotic cells is observed ( Figure 5 ). This is detected both by the TUNEL stain accumulation and also the shrinking of the apoptotic cells from their pre-apoptotic morphology. Once again this demonstrates a potent Dox dependent apoptosis inducing functionality to the polymer-Dex-Dox fi lms.
Discussion and conclusions
As was previously described, PMOXA-PDMS-PMOXA block polymer based hybrid fi lms can act as platforms for localized drug elution (eg, from an implant surface) and be used as an alternative to systemic drug release (Chow et al 2008; Pierstorff et al 2008) . As such, equivalent, or even greater, drug administration at the desired site can be achieved using this technology than from widespread drug delivery, thus increasing effi cacy of treatment. In this study, a dual-therapeutic eluting polymer-hybrid fi lm was constructed that releases functional anti-infl ammatory (Dex) and anti-cancer drugs (Dox). This suggests that the triblock copolymer can provide the both therapeutics to a location from a single device and could be a more effective drug delivery strategy than systemic/solution-based elution. The Langmuir-Blodgett methodology is an excellent proof of concept for the co-deposition of multiple drugs and copolymer at the air-water interface. Continued work will investigate higher throughput deposition methods. It is vital to incorporate anti-infl ammatory functionality to any drug eluting implantable medical device. The decrease in infl ammation will counteract the foreign body response and increase the lifespan of the implanted device and, in the case of an anti-cancer therapeutic drug eluting coating, prolong the time of effective drug release from the device. In addition, increases in IL-6 expression can counteract or have negative impacts on chemotherapy. For example, chronic infl ammation can cause apoptosis in various tissues and even induce the onset of cancer (Hjelstrom 2001; Palapattu et al 2005) , thus, not only increasing the danger of implantation, but also negating the anti-cancer properties of a chemotherapy eluting device. IL-6 has also been implicated in prostate cancer progression via multiple signaling pathways (Giri et al 2001; Park et al 2003) , tumor angiogenesis and infl ammation (Hirano et al 1997; Taga and Kishimoto 1997; Giri et al 2001; Willenberg et al 2002) , tumor progression and pathogenesis (Siegall et al 1990) . As such, both the absence of infl ammation from cellular-nanopolymer interaction and the incorporation of anti-infl ammatory drugs from its matrix make the polymer-hybrid fi lms extremely promising towards clinical and applied nanomedicine.
